TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02520128

Intervention type: RADIATION
Group type: OTHER
Intervention: Intensity modulated radiotherapy (IMRT)
Description: Intensity modulated radiotherapy (IMRT) is an advanced radiotherapy technique that is able to deliver a highly conformal dose to a target with improved sparing of the surrounding normal tissues from moderate to high radiation doses. IMRT is likely to be of particular benefit for tumours that have complex shapes, or those in close proximity to sensitive normal tissues and critical organs. Reducing the dose to normal tissues may in turn reduce the acute and late side effects of treatment. IMRT can be delivered from multiple fixed beam angles or through rotational arc applications such as volumetric modulated arc therapy (VMAT) and tomotherapy. The radiotherapy is delivered using multiple small beams (beamlets) of non-uniform intensity.

Intervention type: RADIATION
Group type: OTHER
Intervention: Intensity modulated radiotherapy (IMRT)
Description: Intensity modulated radiotherapy (IMRT) is an advanced radiotherapy technique that is able to deliver a highly conformal dose to a target with improved sparing of the surrounding normal tissues from moderate to high radiation doses. IMRT is likely to be of particular benefit for tumours that have complex shapes, or those in close proximity to sensitive normal tissues and critical organs. Reducing the dose to normal tissues may in turn reduce the acute and late side effects of treatment. IMRT can be delivered from multiple fixed beam angles or through rotational arc applications such as volumetric modulated arc therapy (VMAT) and tomotherapy. The radiotherapy is delivered using multiple small beams (beamlets) of non-uniform intensity.

Intervention type: RADIATION
Group type: OTHER
Intervention: Intensity modulated radiotherapy (IMRT)
Description: Intensity modulated radiotherapy (IMRT) is an advanced radiotherapy technique that is able to deliver a highly conformal dose to a target with improved sparing of the surrounding normal tissues from moderate to high radiation doses. IMRT is likely to be of particular benefit for tumours that have complex shapes, or those in close proximity to sensitive normal tissues and critical organs. Reducing the dose to normal tissues may in turn reduce the acute and late side effects of treatment. IMRT can be delivered from multiple fixed beam angles or through rotational arc applications such as volumetric modulated arc therapy (VMAT) and tomotherapy. The radiotherapy is delivered using multiple small beams (beamlets) of non-uniform intensity.
Study: NCT01525212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-929075
Description: Oral Suspension, (≤ 800 mg, Once daily) OR (≤ 400 mg, Twice daily), 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching BMS-929075
Description: Oral Suspension, 0 mg, Once daily, 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching BMS-929075
Description: Oral Suspension, 0 mg, Once daily, 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching BMS-929075
Description: Oral Suspension, 0 mg, Once daily, 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching BMS-929075
Description: Oral Suspension, 0 mg, (Once daily for ≤ 800 mg group) OR (Twice daily for ≤ 400 mg group), 3 days
Study: NCT03320733

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Dual energy CT scan with subtraction imaging
Description: The single source V2R kmAS dual energy CT system has several theoretical advantages compared, such as perfectly matched X-ray paths and the possibility of performing dual-energy processing using projection data.~Subtraction imaging is an accurate deformable registration algorithm that allows creation of iodine maps from matched pre- and post-contrast acquisitions. This algorithm can be applied to both single and dual energy CT.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Dual energy CT scan with subtraction imaging
Description: The single source V2R kmAS dual energy CT system has several theoretical advantages compared, such as perfectly matched X-ray paths and the possibility of performing dual-energy processing using projection data.~Subtraction imaging is an accurate deformable registration algorithm that allows creation of iodine maps from matched pre- and post-contrast acquisitions. This algorithm can be applied to both single and dual energy CT.
Study: NCT02436798

Intervention type: DRUG
Intervention: Ondansetron
Description: All patients will be receiving treatment with ondansetron as part of standard care.
Study: NCT03558412

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CODOX-M/IVAC
Description: Given ivgtt

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given ivgtt
Study: NCT04307745

Intervention type: OTHER
Intervention: Primary prevention
Description: The primary prevention that the 4 groups put in place for the upper limp athletes

Intervention type: OTHER
Intervention: Primary prevention
Description: The primary prevention that the 4 groups put in place for the upper limp athletes
Study: NCT00035815

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin like growth factor, type 1
Description: 0.05 mg per kg body weight given subcutaneously twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo represented the inert suspension vehicle for the IGF-1. It was given as equal volume as the active drug based upon body weight, subcutaneously twice daily.
Study: NCT02796989

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Wheat bran
Description: 20 g each day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Wheat bran
Description: 20 g each day
Study: NCT04432298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamrevlumab
Description: Sterile liquid for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sterile liquid for injection
Study: NCT02796989

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 20 g each day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 20 g each day
Study: NCT04307745

Intervention type: OTHER
Intervention: Primary prevention
Description: The primary prevention that the 4 groups put in place for the upper limp athletes
Study: NCT04795180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irrigations trough the efferent limb of loop ileostomy
Description: Irrigations trough the efferent limb of loop ileostomy during 4 weeks previous to ileostomy closure
Study: NCT03915054

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AREG-TRIGGER
Description: Oocytes in AREG-TRIGGER medium will be mature in AREG + FSH + HSA + Insulin + Estradiol medium.~Per case (6mL) 5940 µL Basal Medium~* 60 µL IVM MIX Do not need to filtrate media.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CONTROL-TRIGGER
Description: Oocytes in CONTROL-TRIGGER medium will be mature in FSH + hCG + GH + HSA medium.~Per case (5 mL) 4.3 ml IVM Medicult Medium (Vial 2) 0.5 ml HSA (from stock 10% solution) 50µl FSH (from stock 7.5 IU/ml) 5µl hCG (from stock 100 IU/ml) 75 µl GH (from stock 0.66mg/ml)
Study: NCT01881633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISU302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISU302
Study: NCT04795180

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Irrigations trough the efferent limb of loop ileostomy
Description: Irrigations trough the efferent limb of loop ileostomy during 4 weeks previous to ileostomy closure
Study: NCT05143801

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-intensity interval exercise without using a surgical face mask in a hot environment
Description: Participants performed high-intensity interval exercise in a hot environmental condition without wearing a surgical face mask

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-intensity interval exercise without using a surgical face mask in a temperate environment
Description: Participants performed high-intensity interval exercise in a temperate environmental condition without wearing a surgical face mask
Study: NCT00973219

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peg-Interferon alfa 2a + Adefovir dipivoxil, Peg-Interferon alfa 2a + Tenofovir disoproxil fumarate
Description: Peg-Interferon alfa 2a 180ug/week + Adefovir dipivoxil 10mg/day, Peg-Interferon alfa 2a 180ug/week + Tenofovir disoproxil fumarate 245mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peg-Interferon alfa 2a + Adefovir dipivoxil, Peg-Interferon alfa 2a + Tenofovir disoproxil fumarate
Description: Peg-Interferon alfa 2a 180ug/week + Adefovir dipivoxil 10mg/day, Peg-Interferon alfa 2a 180ug/week + Tenofovir disoproxil fumarate 245mg/day
Study: NCT01726933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS41008
Description: gastric resistant tablet, weekly up-titration up to maximal tolerated dosage

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LASW1835
Description: gastric resistant tablet, weekly up-titration up to maximal tolerated dosage

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: gastric resistant tablet, weekly up-titration up to maximal tolerated dosage
Study: NCT01002287

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SprayShield Adhesion Barrier System
Description: Adhesion Barrier Device

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Good Surgical Technique Alone
Description: Good Surgical Technique Alone
Study: NCT02742389

Intervention type: OTHER
Group type: OTHER
Intervention: Preprocedure Telephone Call
Description: The participants will receive a phone call from the investigators 1 week before their testing to talk about the procedure and answer any questions that patients may have . The investigator calling the participant will document the duration of the phone call and any questions asked by the participant
Study: NCT04430530

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infusion of 4SCAR-T specific to CD22/CD123/CD38/ CD10/CD20
Description: Patients who have relapsed after anti-CD19 immunotherapy or have CD19 negative B cell malignancies
Study: NCT01881633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISU302

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01336972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Description: Tolvaptan was supplied as 15 and 30 mg tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Description: Tolvaptan was supplied as 15 and 30 mg tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Description: Tolvaptan was supplied as 15 and 30 mg tablets.
Study: NCT03749174

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Long acting Supraclivicular block vs Short acting Supraclavicular block
Description: Patients are randomized to receive; long-acting Supraclavicular plexus block or short-acting Supraclavicular plexus block or general anesthesia~Sub group randomized to plaster/cast or orthosis/brace, both having short-acting block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Long acting Supraclivicular block vs Short acting Supraclavicular block
Description: Patients are randomized to receive; long-acting Supraclavicular plexus block or short-acting Supraclavicular plexus block or general anesthesia~Sub group randomized to plaster/cast or orthosis/brace, both having short-acting block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Long acting Supraclivicular block vs Short acting Supraclavicular block
Description: Patients are randomized to receive; long-acting Supraclavicular plexus block or short-acting Supraclavicular plexus block or general anesthesia~Sub group randomized to plaster/cast or orthosis/brace, both having short-acting block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Long acting Supraclivicular block vs Short acting Supraclavicular block
Description: Patients are randomized to receive; long-acting Supraclavicular plexus block or short-acting Supraclavicular plexus block or general anesthesia~Sub group randomized to plaster/cast or orthosis/brace, both having short-acting block
Study: NCT00176254

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 80 centigray (cGy) on Day 1 \& 2 and 22 \& 23 of chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 225 mg/m2 intravenously over three hours on Days 1 and 22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Area under the curve (AUC) of 6 will be given intravenously over 30 minutes on days 1 and 22
Study: NCT00440739

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoricoxib
Description: etoricoxib 120 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: flavoxate
Description: flavoxate 200 mg 3 times
Study: NCT02095730

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epithelium-On Riboflavin
Description: Riboflavin 0.1% Phosphate Sodium solution with Benzalkonium Chloride Preservative
Study: NCT00440739

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoricoxib, flavoxate
Description: etoricoxib 120 mg once and flavoxate 200 mg 3 times

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo once and placebo 3 times
Study: NCT04952688

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OCT- Angiographie
Description: Ophthalmological examinations
Study: NCT02618733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: 90mg, twice a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: 75mg, once a day
Study: NCT02327247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Felodipine
Description: Extended Release Tablets, 10mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PLENDIL®
Description: Extended Release Tablets, 10mg
Study: NCT00781664

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AN2718
Description: AN2718 Cream SF Vehicle, Daily for up to 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN2718
Description: AN2718 Cream SF, 0.3%, Daily for up to 21 days
Study: NCT02147379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone
Study: NCT02606032

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: active comparator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: active comparator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terbinafine
Description: active comparator
Study: NCT00781664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN2718
Description: AN2718 Cream SF, 1%, Daily for up to 21 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AN2718
Description: AN2718 Gel Vehicle, Daily for up to 21 days
Study: NCT02095730

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epithelium-On Riboflavin
Description: Riboflavin 0.1% Phosphate Sodium solution with Benzalkonium Chloride Preservative

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epithelium-Off Riboflavin
Description: Riboflavin 0.1% Phosphate Sodium solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epithelium-Off Riboflavin
Description: Riboflavin 0.1% Phosphate Sodium solution

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: UV Light - Continuous Beam
Description: 5 minutes of constant UV exposure to saturated cornea

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: UV Light - Continuous Beam
Description: 5 minutes of constant UV exposure to saturated cornea

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: UV Pulsed Beam
Description: 5 minutes of UV exposure to saturated cornea, alternating 1 minute of treatment with 1 minute rest for a total time of 10 minutes

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: UV Pulsed Beam
Description: 5 minutes of UV exposure to saturated cornea, alternating 1 minute of treatment with 1 minute rest for a total time of 10 minutes
Study: NCT04132544

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standardized gerontological evaluation (EGS)
Description: Evaluation (EGS): initially, the patient benefits from a complete EGS and a complete fall balance realized by a Gerontological Assessment Nurse (initial visit V0) in the 7 working days following the intervention of the SAMU for fall. This assessment is based on the EGS and the assessment of risk factors for falls (HAS, INPES).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proposal for a personalized intervention plan (PIP)
Description: A PIP containing personalized recommendations to improve the patient's state of health, treatment and environment as well as risk factors for falls is proposed during the multi-professional consultation and discussed by telephone with the attending physician (pre-arranged telephone appointment). with the latter).~The PIP validated by the attending physician is delivered and explained to the patient by the Gerontological Assessment Nurse in the week following the Multidisciplinary Team Meeting (MDTM) during the V1 visit to the patient's home.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow-up
Description: Four follow-up visits at 6, 12, 18 and 24 months (V2, V3, V4, V5) are performed at the patient's home. During these visits, the Gerontological Assessment Nurse reassesses the person from the gerontological point of view and from the point of view of risk factors for falls.~A mail containing the elements of interest is sent to the attending physician after each visit. The patient is also contacted by telephone by the Gerontological Assessment Nurse at 2, 4, 9, 15 and 21 months of follow-up to maintain a link, identify possible difficulties and encourage him / her to apply the PIP recommendations.
Study: NCT01646294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM178 modified release (OCAS)
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM178 modified release (OCAS)
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM178 modified release (OCAS)
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM178 immediate release (IR)
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM178 immediate release (IR)
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM178 immediate release (IR)
Description: oral
Study: NCT00781664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN2718
Description: AN2718 Gel, 1.5%, Daily for up to 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN2718
Description: AN2718 Gel, 2.5%, Daily for up to 21 days
Study: NCT01687621

Intervention type: PROCEDURE
Intervention: Diagnostic Algorithm for Community Based Worker for Omphalitis
Description: After obtaining guardian informed written consent, newborns aged 1-10 days presenting to the health facility for routine or sick visits would undergo 2 independent, parallel evaluations; first, by a ZamCAT Field Monitor (community level worker from our existing study) and the second by a Zambian medical doctor (gold standard). A US board of pediatrics-certified pediatrician will perform a third independent assessment of a photo of the cord remotely. Using the on-site clinician as the gold standard, the community-based algorithm and the photo assessment will be tested for concordance and the sensitivity and specificity of the algorithm will be generated. Likewise, the remote pictorial assessment will be compared to the gold standard to determine reliability of diagnosis from photographs alone.
Study: NCT02606032

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: identical placebos to all antibiotics
Study: NCT00781664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN2718
Description: AN2718 Gel, 5%, Daily for up to 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN2718
Description: AN2718 Gel, 7.5%, Daily for up to 21 days
Study: NCT04132544

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: The patients included in the control group will benefit from the usual care as well as documentation on general recommendations to be put in place to prevent falls and to age in good health \[series of brochures published by INPES for the elderly. They are informed by telephone of their home group by the Gerontological Assessment Nurse. The documents are sent by mail to the patient's home address.
Study: NCT01351519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminolevulinic Acid
Description: Aminolevulinic Acid will be administered as a single oral dose of 20mg/kg given in 50ml of water three hours before surgery.
Study: NCT01910662

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KLH 0.1 mg
Description: KLH will be administered as single ID injection of 0.1 mg as 0.1mL of KLH (1 mg/mL)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KLH 0.1 mg
Description: KLH will be administered as single ID injection of 0.1 mg as 0.1mL of KLH (1 mg/mL)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KLH 0.1 mg
Description: KLH will be administered as single ID injection of 0.1 mg as 0.1mL of KLH (1 mg/mL)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KLH 5 mg
Description: KLH will be administered as single SC injection of 5 mg

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: KLH 5 mg
Description: KLH will be administered as single SC injection of 5 mg

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PBS (0.1 mL)
Description: PBS will be administered in Part A on Day 1 as 3 ID injections and in Part C: Cohort 1 on Day 1 and Day 2 as a single ID injection
Study: NCT03419247

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fresh tumor tissue biopsy
Description: A type of surgical procedure that will use a thin needle to remove a sample of tumor tissue.
Study: NCT00781664

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Lauryl Sulfate
Description: Sodium Lauryl Sulfate, 0.5%, Daily for up to 21 days
Study: NCT02551809

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-311
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-311
Description: Intramuscular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intramuscular injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular injection
Study: NCT01910662

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PBS (0.1 mL)
Description: PBS will be administered in Part A on Day 1 as 3 ID injections and in Part C: Cohort 1 on Day 1 and Day 2 as a single ID injection
Study: NCT02740582

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tolcapone